APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Toxoplasmosis

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Drugs for Toxoplasmosis Industry Growth and Trends Forecast to 2032

26 December 202599 pages

Choose your research edition.

Industry ResearchDrugs for Toxoplasmosis Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Toxoplasmosis Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Drugs for Toxoplasmosis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Toxoplasmosis Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Toxoplasmosis Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Drugs for Toxoplasmosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Drugs for Toxoplasmosis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Drugs for Toxoplasmosis is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Toxoplasmosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Drugs for Toxoplasmosis include Snowdon, Taj Pharmaceuticals Limited, Turing Pharmaceutical, Glaxo Smithkline Pharmaceuticals Ltd. and Guangzhou Baiyunshan Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Drugs for Toxoplasmosis market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Drugs for Toxoplasmosis market size, estimates, and forecasts are presented in terms of sales volume (K Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Drugs for Toxoplasmosis market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Drugs for Toxoplasmosis.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Drugs for Toxoplasmosis market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Drugs for Toxoplasmosis Market by Company

Snowdon

Taj Pharmaceuticals Limited

Turing Pharmaceutical

Glaxo Smithkline Pharmaceuticals Ltd.

Guangzhou Baiyunshan Pharmaceutical Co., Ltd.

Drugs for Toxoplasmosis Segment by Type

Injection

Tablet

Others

Drugs for Toxoplasmosis Segment by Application

Chronic Toxoplasmosis Treatment

Acute Toxoplasmosis Treatment

Other

Drugs for Toxoplasmosis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Toxoplasmosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Toxoplasmosis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Toxoplasmosis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Drugs for Toxoplasmosis manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Drugs for Toxoplasmosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injection Table 2. Major Company of Tablet Table 3. Major Company of Others Table 4. Global Drugs for Toxoplasmosis Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K Tons) Table 6. Global Drugs for Toxoplasmosis Sales Market Share in Volume by Type (2021-2026) Table 7. Global Drugs for Toxoplasmosis Sales by Type (2021-2026) & (US$ Million) Table 8. Global Drugs for Toxoplasmosis Sales Market Share in Value by Type (2021-2026) Table 9. Global Drugs for Toxoplasmosis Price by Type (2021-2026) & (US$/Ton) Table 10. Global Drugs for Toxoplasmosis Sales by Type (2027-2032) & (K Tons) Table 11. Global Drugs for Toxoplasmosis Sales Market Share in Volume by Type (2027-2032) Table 12. Global Drugs for Toxoplasmosis Sales by Type (2027-2032) & (US$ Million) Table 13. Global Drugs for Toxoplasmosis Sales Market Share in Value by Type (2027-2032) Table 14. Global Drugs for Toxoplasmosis Price by Type (2027-2032) & (US$/Ton) Table 15. North America Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K Tons) Table 16. North America Drugs for Toxoplasmosis Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K Tons) Table 18. Europe Drugs for Toxoplasmosis Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K Tons) Table 20. Asia-Pacific Drugs for Toxoplasmosis Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K Tons) Table 22. Latin America Drugs for Toxoplasmosis Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Drugs for Toxoplasmosis Sales by Type (2021-2026) & (K Tons) Table 24. Middle East and Africa Drugs for Toxoplasmosis Sales by Type (2021-2026) & (US$ Million) Table 25. Drugs for Toxoplasmosis Industry Trends Table 26. Drugs for Toxoplasmosis Industry Drivers Table 27. Drugs for Toxoplasmosis Industry Opportunities and Challenges Table 28. Drugs for Toxoplasmosis Industry Restraints Table 29. Global Drugs for Toxoplasmosis Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Drugs for Toxoplasmosis Revenue Market Share by Company (2021-2026) Table 31. Global Drugs for Toxoplasmosis Sales by Company (2021-2026) & (K Tons) Table 32. Global Drugs for Toxoplasmosis Sales Share by Company (2021-2026) Table 33. Global Drugs for Toxoplasmosis Market Price by Company (2021-2026) & (US$/Ton) Table 34. Global Drugs for Toxoplasmosis Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Drugs for Toxoplasmosis Major Company Production Sites and Headquarters Table 36. Global Drugs for Toxoplasmosis Company, Product Type & Application Table 37. Global Drugs for Toxoplasmosis Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Drugs for Toxoplasmosis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Drugs for Toxoplasmosis Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Drugs for Toxoplasmosis Sales by Region (2021-2026) & (K Tons) Table 42. Global Drugs for Toxoplasmosis Sales Market Share in Volume by Region (2021-2026) Table 43. Global Drugs for Toxoplasmosis Sales by Region (2021-2026) & (US$ Million) Table 44. Global Drugs for Toxoplasmosis Sales Market Share in Value by Region (2021-2026) Table 45. Global Drugs for Toxoplasmosis Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 46. Global Drugs for Toxoplasmosis Sales by Region (2027-2032) & (K Tons) Table 47. Global Drugs for Toxoplasmosis Sales Market Share in Volume by Region (2027-2032) Table 48. Global Drugs for Toxoplasmosis Sales by Region (2027-2032) & (US$ Million) Table 49. Global Drugs for Toxoplasmosis Sales Market Share in Value by Region (2027-2032) Table 50. Global Drugs for Toxoplasmosis Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2027-2032) Table 51. Global Drugs for Toxoplasmosis Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K Tons) Table 53. Global Drugs for Toxoplasmosis Sales Market Share in Volume by Application (2021-2026) Table 54. Global Drugs for Toxoplasmosis Sales by Application (2021-2026) & (US$ Million) Table 55. Global Drugs for Toxoplasmosis Sales Market Share in Value by Application (2021-2026) Table 56. Global Drugs for Toxoplasmosis Price by Application (2021-2026) & (US$/Ton) Table 57. Global Drugs for Toxoplasmosis Sales by Application (2027-2032) & (K Tons) Table 58. Global Drugs for Toxoplasmosis Sales Market Share in Volume by Application (2027-2032) Table 59. Global Drugs for Toxoplasmosis Sales by Application (2027-2032) & (US$ Million) Table 60. Global Drugs for Toxoplasmosis Sales Market Share in Value by Application (2027-2032) Table 61. Global Drugs for Toxoplasmosis Price by Application (2027-2032) & (US$/Ton) Table 62. North America Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K Tons) Table 63. North America Drugs for Toxoplasmosis Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K Tons) Table 65. Europe Drugs for Toxoplasmosis Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K Tons) Table 67. Asia-Pacific Drugs for Toxoplasmosis Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K Tons) Table 69. Latin America Drugs for Toxoplasmosis Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Drugs for Toxoplasmosis Sales by Application (2021-2026) & (K Tons) Table 71. Middle East and Africa Drugs for Toxoplasmosis Sales by Application (2021-2026) & (US$ Million) Table 72. Snowdon Company Information Table 73. Snowdon Business Overview Table 74. Snowdon Drugs for Toxoplasmosis Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 75. Snowdon Drugs for Toxoplasmosis Product Portfolio Table 76. Snowdon Recent Development Table 77. Taj Pharmaceuticals Limited Company Information Table 78. Taj Pharmaceuticals Limited Business Overview Table 79. Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 80. Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Product Portfolio Table 81. Taj Pharmaceuticals Limited Recent Development Table 82. Turing Pharmaceutical Company Information Table 83. Turing Pharmaceutical Business Overview Table 84. Turing Pharmaceutical Drugs for Toxoplasmosis Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 85. Turing Pharmaceutical Drugs for Toxoplasmosis Product Portfolio Table 86. Turing Pharmaceutical Recent Development Table 87. Glaxo Smithkline Pharmaceuticals Ltd. Company Information Table 88. Glaxo Smithkline Pharmaceuticals Ltd. Business Overview Table 89. Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 90. Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Product Portfolio Table 91. Glaxo Smithkline Pharmaceuticals Ltd. Recent Development Table 92. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Company Information Table 93. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Business Overview Table 94. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Sales (K Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 95. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Product Portfolio Table 96. Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Recent Development Table 97. North America Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (K Tons): 2021 VS 2025 VS 2032 Table 98. North America Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K Tons) Table 99. North America Drugs for Toxoplasmosis Sales Market Share by Country (2021-2026) Table 100. North America Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032) & (K Tons) Table 101. North America Drugs for Toxoplasmosis Sales Market Share Forecast by Country (2027-2032) Table 102. North America Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 103. North America Drugs for Toxoplasmosis Market Size by Country (2021-2026) & (US$ Million) Table 104. North America Drugs for Toxoplasmosis Market Share by Country (2021-2026) Table 105. North America Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 106. North America Drugs for Toxoplasmosis Market Share Forecast by Country (2027-2032) Table 107. Europe Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (K Tons): 2021 VS 2025 VS 2032 Table 108. Europe Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K Tons) Table 109. Europe Drugs for Toxoplasmosis Sales Market Share by Country (2021-2026) Table 110. Europe Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032) & (K Tons) Table 111. Europe Drugs for Toxoplasmosis Sales Market Share Forecast by Country (2027-2032) Table 112. Europe Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. Europe Drugs for Toxoplasmosis Market Size by Country (2021-2026) & (US$ Million) Table 114. Europe Drugs for Toxoplasmosis Market Share by Country (2021-2026) Table 115. Europe Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. Europe Drugs for Toxoplasmosis Market Share Forecast by Country (2027-2032) Table 117. Asia-Pacific Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (K Tons): 2021 VS 2025 VS 2032 Table 118. Asia-Pacific Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K Tons) Table 119. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share by Country (2021-2026) Table 120. Asia-Pacific Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032) & (K Tons) Table 121. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share Forecast by Country (2027-2032) Table 122. Asia-Pacific Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Asia-Pacific Drugs for Toxoplasmosis Market Size by Country (2021-2026) & (US$ Million) Table 124. Asia-Pacific Drugs for Toxoplasmosis Market Share by Country (2021-2026) Table 125. Asia-Pacific Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Asia-Pacific Drugs for Toxoplasmosis Market Share Forecast by Country (2027-2032) Table 127. Latin America Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (K Tons): 2021 VS 2025 VS 2032 Table 128. Latin America Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K Tons) Table 129. Latin America Drugs for Toxoplasmosis Sales Market Share by Country (2021-2026) Table 130. Latin America Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032) & (K Tons) Table 131. Latin America Drugs for Toxoplasmosis Sales Market Share Forecast by Country (2027-2032) Table 132. Latin America Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Latin America Drugs for Toxoplasmosis Market Size by Country (2021-2026) & (US$ Million) Table 134. Latin America Drugs for Toxoplasmosis Market Share by Country (2021-2026) Table 135. Latin America Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Latin America Drugs for Toxoplasmosis Market Share Forecast by Country (2027-2032) Table 137. Middle East and Africa Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (K Tons): 2021 VS 2025 VS 2032 Table 138. Middle East and Africa Drugs for Toxoplasmosis Sales by Country (2021-2026) & (K Tons) Table 139. Middle East and Africa Drugs for Toxoplasmosis Sales Market Share by Country (2021-2026) Table 140. Middle East and Africa Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032) & (K Tons) Table 141. Middle East and Africa Drugs for Toxoplasmosis Sales Market Share Forecast by Country (2027-2032) Table 142. Middle East and Africa Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Middle East and Africa Drugs for Toxoplasmosis Market Size by Country (2021-2026) & (US$ Million) Table 144. Middle East and Africa Drugs for Toxoplasmosis Market Share by Country (2021-2026) Table 145. Middle East and Africa Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Middle East and Africa Drugs for Toxoplasmosis Market Share Forecast by Country (2027-2032) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Drugs for Toxoplasmosis Distributors List Table 150. Drugs for Toxoplasmosis Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Drugs for Toxoplasmosis Image Figure 2. Global Drugs for Toxoplasmosis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Toxoplasmosis Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Toxoplasmosis Sales (2021-2032) & (K Tons) Figure 5. Injection Image Figure 6. Global Injection Sales YoY Growth (2021-2032) & (K Tons) Figure 7. Tablet Image Figure 8. Global Tablet Sales YoY Growth (2021-2032) & (K Tons) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (K Tons) Figure 11. Global Drugs for Toxoplasmosis Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Drugs for Toxoplasmosis Market Share by Type 2025 VS 2032 Figure 13. North America Drugs for Toxoplasmosis Sales Market Share in Volume by Type in 2025 Figure 14. North America Drugs for Toxoplasmosis Sales Market Share in Value by Type in 2025 Figure 15. Europe Drugs for Toxoplasmosis Sales Market Share in Volume by Type in 2025 Figure 16. Europe Drugs for Toxoplasmosis Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share in Value by Type in 2025 Figure 19. Latin America Drugs for Toxoplasmosis Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Drugs for Toxoplasmosis Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Drugs for Toxoplasmosis Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Drugs for Toxoplasmosis Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Drugs for Toxoplasmosis Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Chronic Toxoplasmosis Treatment Image Figure 26. Global Chronic Toxoplasmosis Treatment Sales YoY Growth (2021-2032) & (K Tons) Figure 27. Acute Toxoplasmosis Treatment Image Figure 28. Global Acute Toxoplasmosis Treatment Sales YoY Growth (2021-2032) & (K Tons) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Tons) Figure 31. Global Drugs for Toxoplasmosis Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Drugs for Toxoplasmosis Market Share by Application 2025 VS 2032 Figure 33. North America Drugs for Toxoplasmosis Sales Market Share in Volume by Application in 2025 Figure 34. North America Drugs for Toxoplasmosis Sales Market Share in Value by Application in 2025 Figure 35. Europe Drugs for Toxoplasmosis Sales Market Share in Volume by Application in 2025 Figure 36. Europe Drugs for Toxoplasmosis Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Drugs for Toxoplasmosis Sales Market Share in Value by Application in 2025 Figure 39. Latin America Drugs for Toxoplasmosis Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Drugs for Toxoplasmosis Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Drugs for Toxoplasmosis Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Drugs for Toxoplasmosis Sales Market Share in Value by Application in 2025 Figure 43. North America Drugs for Toxoplasmosis Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Figure 44. North America Drugs for Toxoplasmosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Drugs for Toxoplasmosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Drugs for Toxoplasmosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Drugs for Toxoplasmosis Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Figure 48. Europe Drugs for Toxoplasmosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Drugs for Toxoplasmosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Drugs for Toxoplasmosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Drugs for Toxoplasmosis Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Figure 52. Asia-Pacific Drugs for Toxoplasmosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Drugs for Toxoplasmosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Drugs for Toxoplasmosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Drugs for Toxoplasmosis Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Figure 56. Latin America Drugs for Toxoplasmosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Drugs for Toxoplasmosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Drugs for Toxoplasmosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Drugs for Toxoplasmosis Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Figure 60. Middle East and Africa Drugs for Toxoplasmosis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Drugs for Toxoplasmosis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Drugs for Toxoplasmosis Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Drugs for Toxoplasmosis Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Drugs for Toxoplasmosis Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Tablet
  • Others
Applications
  • Chronic Toxoplasmosis Treatment
  • Acute Toxoplasmosis Treatment
  • Other
Companies covered
  • Snowdon
  • Taj Pharmaceuticals Limited
  • Turing Pharmaceutical
  • Glaxo Smithkline Pharmaceuticals Ltd.
  • Guangzhou Baiyunshan Pharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for Toxoplasmosis Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Drugs for Toxoplasmosis Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Drugs for Toxoplasmosis Market by Type
  6. 1.3.1 Injection
  7. 1.3.2 Tablet
  8. 1.3.3 Others
  9. 1.4 Global Drugs for Toxoplasmosis Market Size by Type
  10. 1.4.1 Global Drugs for Toxoplasmosis Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Drugs for Toxoplasmosis Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Drugs for Toxoplasmosis Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Drugs for Toxoplasmosis Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Drugs for Toxoplasmosis Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Drugs for Toxoplasmosis Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Drugs for Toxoplasmosis Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Drugs for Toxoplasmosis Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Drugs for Toxoplasmosis Industry Trends
  2. 2.2 Drugs for Toxoplasmosis Industry Drivers
  3. 2.3 Drugs for Toxoplasmosis Industry Opportunities and Challenges
  4. 2.4 Drugs for Toxoplasmosis Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Drugs for Toxoplasmosis Revenue (2021-2026)
  2. 3.2 Global Top Players by Drugs for Toxoplasmosis Sales (2021-2026)
  3. 3.3 Global Top Players by Drugs for Toxoplasmosis Price (2021-2026)
  4. 3.4 Global Drugs for Toxoplasmosis Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Drugs for Toxoplasmosis Major Company Production Sites & Headquarters
  6. 3.6 Global Drugs for Toxoplasmosis Company, Product Type & Application
  7. 3.7 Global Drugs for Toxoplasmosis Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Drugs for Toxoplasmosis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Drugs for Toxoplasmosis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Drugs for Toxoplasmosis Tier 1, Tier 2, and Tier 3
4 Drugs for Toxoplasmosis Regional Status and Outlook
  1. 4.1 Global Drugs for Toxoplasmosis Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Drugs for Toxoplasmosis Historic Market Size by Region
  3. 4.2.1 Global Drugs for Toxoplasmosis Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Drugs for Toxoplasmosis Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Drugs for Toxoplasmosis Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Drugs for Toxoplasmosis Forecasted Market Size by Region
  7. 4.3.1 Global Drugs for Toxoplasmosis Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Drugs for Toxoplasmosis Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Drugs for Toxoplasmosis Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Drugs for Toxoplasmosis by Application
  1. 5.1 Drugs for Toxoplasmosis Market by Application
  2. 5.1.1 Chronic Toxoplasmosis Treatment
  3. 5.1.2 Acute Toxoplasmosis Treatment
  4. 5.1.3 Other
  5. 5.2 Global Drugs for Toxoplasmosis Market Size by Application
  6. 5.2.1 Global Drugs for Toxoplasmosis Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Drugs for Toxoplasmosis Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Drugs for Toxoplasmosis Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Drugs for Toxoplasmosis Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Drugs for Toxoplasmosis Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Drugs for Toxoplasmosis Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Drugs for Toxoplasmosis Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Drugs for Toxoplasmosis Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Snowdon
  2. 6.1.1 Snowdon Company Information
  3. 6.1.2 Snowdon Business Overview
  4. 6.1.3 Snowdon Drugs for Toxoplasmosis Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Snowdon Drugs for Toxoplasmosis Product Portfolio
  6. 6.1.5 Snowdon Recent Developments
  7. 6.2 Taj Pharmaceuticals Limited
  8. 6.2.1 Taj Pharmaceuticals Limited Company Information
  9. 6.2.2 Taj Pharmaceuticals Limited Business Overview
  10. 6.2.3 Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Taj Pharmaceuticals Limited Drugs for Toxoplasmosis Product Portfolio
  12. 6.2.5 Taj Pharmaceuticals Limited Recent Developments
  13. 6.3 Turing Pharmaceutical
  14. 6.3.1 Turing Pharmaceutical Company Information
  15. 6.3.2 Turing Pharmaceutical Business Overview
  16. 6.3.3 Turing Pharmaceutical Drugs for Toxoplasmosis Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Turing Pharmaceutical Drugs for Toxoplasmosis Product Portfolio
  18. 6.3.5 Turing Pharmaceutical Recent Developments
  19. 6.4 Glaxo Smithkline Pharmaceuticals Ltd.
  20. 6.4.1 Glaxo Smithkline Pharmaceuticals Ltd. Company Information
  21. 6.4.2 Glaxo Smithkline Pharmaceuticals Ltd. Business Overview
  22. 6.4.3 Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Glaxo Smithkline Pharmaceuticals Ltd. Drugs for Toxoplasmosis Product Portfolio
  24. 6.4.5 Glaxo Smithkline Pharmaceuticals Ltd. Recent Developments
  25. 6.5 Guangzhou Baiyunshan Pharmaceutical Co., Ltd.
  26. 6.5.1 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Company Information
  27. 6.5.2 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Business Overview
  28. 6.5.3 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Drugs for Toxoplasmosis Product Portfolio
  30. 6.5.5 Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Recent Developments
7 North America by Country
  1. 7.1 North America Drugs for Toxoplasmosis Sales by Country
  2. 7.1.1 North America Drugs for Toxoplasmosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Drugs for Toxoplasmosis Sales by Country (2021-2026)
  4. 7.1.3 North America Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032)
  5. 7.2 North America Drugs for Toxoplasmosis Market Size by Country
  6. 7.2.1 North America Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Drugs for Toxoplasmosis Market Size by Country (2021-2026)
  8. 7.2.3 North America Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Drugs for Toxoplasmosis Sales by Country
  2. 8.1.1 Europe Drugs for Toxoplasmosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Drugs for Toxoplasmosis Sales by Country (2021-2026)
  4. 8.1.3 Europe Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Drugs for Toxoplasmosis Market Size by Country
  6. 8.2.1 Europe Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Drugs for Toxoplasmosis Market Size by Country (2021-2026)
  8. 8.2.3 Europe Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Drugs for Toxoplasmosis Sales by Country
  2. 9.1.1 Asia-Pacific Drugs for Toxoplasmosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Drugs for Toxoplasmosis Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Drugs for Toxoplasmosis Market Size by Country
  6. 9.2.1 Asia-Pacific Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Drugs for Toxoplasmosis Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Drugs for Toxoplasmosis Sales by Country
  2. 10.1.1 South America Drugs for Toxoplasmosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Drugs for Toxoplasmosis Sales by Country (2021-2026)
  4. 10.1.3 South America Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032)
  5. 10.2 South America Drugs for Toxoplasmosis Market Size by Country
  6. 10.2.1 South America Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Drugs for Toxoplasmosis Market Size by Country (2021-2026)
  8. 10.2.3 South America Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Drugs for Toxoplasmosis Sales by Country
  2. 11.1.1 Middle East and Africa Drugs for Toxoplasmosis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Drugs for Toxoplasmosis Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Drugs for Toxoplasmosis Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Drugs for Toxoplasmosis Market Size by Country
  6. 11.2.1 Middle East and Africa Drugs for Toxoplasmosis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Drugs for Toxoplasmosis Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Drugs for Toxoplasmosis Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Drugs for Toxoplasmosis Value Chain Analysis
  2. 12.1.1 Drugs for Toxoplasmosis Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Drugs for Toxoplasmosis Production Mode & Process
  7. 12.2 Drugs for Toxoplasmosis Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Drugs for Toxoplasmosis Distributors
  10. 12.2.3 Drugs for Toxoplasmosis Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst